JP5990102B2 - ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 - Google Patents

ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 Download PDF

Info

Publication number
JP5990102B2
JP5990102B2 JP2012531516A JP2012531516A JP5990102B2 JP 5990102 B2 JP5990102 B2 JP 5990102B2 JP 2012531516 A JP2012531516 A JP 2012531516A JP 2012531516 A JP2012531516 A JP 2012531516A JP 5990102 B2 JP5990102 B2 JP 5990102B2
Authority
JP
Japan
Prior art keywords
seq
disease
protein
mannosidase
mannose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012531516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505735A5 (https=
JP2013505735A (ja
Inventor
ニコ リュック マルク カレヴェルト，
ニコ リュック マルク カレヴェルト，
ヴァウテル フェルフェケン，
ヴァウテル フェルフェケン，
ペトラ ソフィー ティールス，
ペトラ ソフィー ティールス，
ハン カレル レマウト，
ハン カレル レマウト，
カトレーン カミリア テレスポレ アリダ マリア ピーンス，
カトレーン カミリア テレスポレ アリダ マリア ピーンス，
Original Assignee
ユニフェルシテイト ヘント
ユニフェルシテイト ヘント
フェーイーベー フェーゼットヴェー
フェーイーベー フェーゼットヴェー
オキシレイン ユーケー リミテッド
オキシレイン ユーケー リミテッド
フレイエ ユニフェルシテイト ブリュッセル
フレイエ ユニフェルシテイト ブリュッセル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニフェルシテイト ヘント, ユニフェルシテイト ヘント, フェーイーベー フェーゼットヴェー, フェーイーベー フェーゼットヴェー, オキシレイン ユーケー リミテッド, オキシレイン ユーケー リミテッド, フレイエ ユニフェルシテイト ブリュッセル, フレイエ ユニフェルシテイト ブリュッセル filed Critical ユニフェルシテイト ヘント
Publication of JP2013505735A publication Critical patent/JP2013505735A/ja
Publication of JP2013505735A5 publication Critical patent/JP2013505735A5/ja
Application granted granted Critical
Publication of JP5990102B2 publication Critical patent/JP5990102B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2477—Hemicellulases not provided in a preceding group
    • C12N9/2488—Mannanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012531516A 2009-09-29 2010-09-29 ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解 Expired - Fee Related JP5990102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24684709P 2009-09-29 2009-09-29
US61/246,847 2009-09-29
PCT/IB2010/002589 WO2011039634A2 (en) 2009-09-29 2010-09-29 Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016042290A Division JP6392263B2 (ja) 2009-09-29 2016-03-04 ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解

Publications (3)

Publication Number Publication Date
JP2013505735A JP2013505735A (ja) 2013-02-21
JP2013505735A5 JP2013505735A5 (https=) 2013-11-07
JP5990102B2 true JP5990102B2 (ja) 2016-09-07

Family

ID=43706307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012531516A Expired - Fee Related JP5990102B2 (ja) 2009-09-29 2010-09-29 ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解
JP2016042290A Expired - Fee Related JP6392263B2 (ja) 2009-09-29 2016-03-04 ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016042290A Expired - Fee Related JP6392263B2 (ja) 2009-09-29 2016-03-04 ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解

Country Status (10)

Country Link
US (2) US9598682B2 (https=)
EP (1) EP2483399B1 (https=)
JP (2) JP5990102B2 (https=)
KR (2) KR102000383B1 (https=)
CN (2) CN102712914A (https=)
BR (1) BR112012007099A2 (https=)
CA (1) CA2775938C (https=)
DK (1) DK2483399T3 (https=)
ES (1) ES2783024T3 (https=)
WO (1) WO2011039634A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887752C (en) * 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
WO2011061629A2 (en) 2009-11-19 2011-05-26 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
CA2812872C (en) 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
US20150031081A1 (en) 2011-12-30 2015-01-29 Oxyrane Uk Limited Methods and materials for reducing degradation of recombinant proteins
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
CN105658801A (zh) 2013-08-27 2016-06-08 诺沃吉公司 经工程改造以利用非常规的磷或硫源的微生物
MX2016002720A (es) * 2013-09-06 2016-06-08 Hoffmann La Roche Metodo para mejorar la estabilidad del anticuerpo.
CN114540327B (zh) * 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3393501B1 (en) * 2015-12-24 2023-06-07 Oxyrane UK Limited Human alpha-n-acetylgalactosaminidase polypeptide
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
CA3019354A1 (en) * 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
WO2018046774A1 (en) * 2016-09-12 2018-03-15 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
SMT202300187T1 (it) * 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
CN111148844A (zh) 2017-09-01 2020-05-12 韦恩生物科技股份公司 鉴定和使用糖肽作为诊断和治疗监测的生物标记物
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
US20220125892A1 (en) * 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
CN115725546B (zh) * 2022-10-13 2024-11-26 湖南大学 具有激活植物免疫功能的α-甘露糖苷酶及应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
JPS575458A (en) 1980-06-13 1982-01-12 Hashimoto Corp Automatic answering telephone device controlled with digital counter
JPS5754588A (en) 1980-09-19 1982-04-01 Eiji Ichijima Alpha-mannosidase
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
ATE156344T1 (de) 1991-04-25 1997-08-15 Univ Brown Res Found Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5834251A (en) 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
WO1997044470A1 (en) 1996-05-21 1997-11-27 Novo Nordisk A/S Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
CA2258307C (en) 1996-07-05 2008-02-12 Novo Nordisk A/S Method of producing heterologous short chain polypeptides by yeast with impaired yap3 protease
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
PT975775E (pt) 1997-04-23 2004-07-30 Vlaams Interuniv Inst Biotech Sistema regulador para a expressao induzivel de genes com promotores lambdoides
US7442772B2 (en) 1997-12-03 2008-10-28 Genentech, Inc. Antibodies to PRO361 polypeptide
WO1999037758A2 (en) 1998-01-27 1999-07-29 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Expression of proteolytically-sensitive peptides
WO2001042462A2 (en) 1999-12-08 2001-06-14 National University Of Singapore Phospholipase a2 inhibitory peptides from python reticulatus
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127219A1 (en) 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
EP1283265B1 (en) 2000-05-17 2009-08-05 Mitsubishi Tanabe Pharma Corporation Process for producing protein with reduction of mannose phosphate in the sugar chain and glycoprotein produced thereby
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
EP1294910B1 (en) 2000-06-30 2008-11-19 VIB vzw Protein glycosylation modification in pichia pastoris
ES2258371B1 (es) 2000-08-31 2007-05-16 Dong Kook Pharmaceutical Co. Ltd. Levadura transformante productora de hormona paratiroidea humana y procedimiento para producir la hormona.
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4742191B2 (ja) 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
JP4774496B2 (ja) 2001-06-14 2011-09-14 独立行政法人産業技術総合研究所 α−マンノシダーゼ
DK2093286T3 (da) 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
CA2471551C (en) 2001-12-27 2014-09-30 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
US7972809B2 (en) 2002-04-26 2011-07-05 National Institute Of Advanced Industrial Science & Technology Methylotrophic yeast producing mammalian type sugar chain
IL165717A0 (en) 2002-06-26 2006-01-15 Flanders Interuniversity Inst A strain of methylotrophic yeast for producing proteins
EP1534835B1 (en) 2002-06-29 2010-09-08 Korea Research Institute of Bioscience and Biotechnology Hansenula polymorpha yapsin deficient mutant strain and process for the preparation of recombinant proteins using the same
KR100470978B1 (ko) 2003-01-02 2005-03-10 한국생명공학연구원 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법
AU2012206984B2 (en) 2003-02-11 2015-07-09 Takeda Pharmaceutical Company Limited Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE)
ATE374825T1 (de) 2003-02-21 2007-10-15 Biotecnol Sa Verwendung von caspasen zur herstellung von reifen rekombinanten fusionsproteinen
JP4259169B2 (ja) 2003-04-16 2009-04-30 昭和産業株式会社 新規α−１，２−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法
US7259255B2 (en) 2003-06-25 2007-08-21 E. I. Du Pont De Nemours And Company Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast
CA2551484C (en) 2003-12-24 2015-03-31 Glycofi, Inc. Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
WO2005089047A2 (en) 2004-03-18 2005-09-29 Glycofi, Inc. Glycosylated glucocerebrosidase expression in fungal hosts
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
CN101084233B (zh) 2004-04-29 2012-08-15 格利科菲公司 用于在糖蛋白产生中减少或消除α-甘露糖苷酶抗性聚糖的方法
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20060014264A1 (en) 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
EP1910514A4 (en) 2005-04-14 2010-03-03 Oxyrane Uk Ltd RECOMBINANT HEEDS FOR SYNTHETIZING EPOXY HYDROLASES
EP1934605B1 (en) 2005-09-22 2014-03-26 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20080081035A1 (en) 2006-10-03 2008-04-03 National Enzyme Company Therapeutic protease compositions
JP2010517577A (ja) 2007-02-09 2010-05-27 メディミューン，エルエルシー 酵母細胞原形質膜による抗体ライブラリー提示
CA2887752C (en) 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
WO2008143354A1 (ja) 2007-05-18 2008-11-27 Tokyo Metropolitan Organization For Medical Research 酵素補充療法用医薬組成物
WO2009033507A1 (en) 2007-09-14 2009-03-19 Telefonaktiebolaget Lm Ericsson (Publ) User data notification in a mobile communications system
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US20100311122A1 (en) 2008-02-20 2010-12-09 Glycofi, Inc Vectors and yeast strains for protein production
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
WO2010099195A1 (en) 2009-02-26 2010-09-02 Glaxosmithkline Llc. Host cells and methods of use
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
WO2011061629A2 (en) 2009-11-19 2011-05-26 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
JP2013517761A (ja) 2010-01-21 2013-05-20 オキシレイン ユーケー リミテッド 酵母細胞の表面上にポリペプチドをディスプレイするための方法および組成物
US20120135461A1 (en) 2010-07-30 2012-05-31 William James Cook Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase
CA2812872C (en) 2010-09-29 2021-08-03 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
US20150031081A1 (en) 2011-12-30 2015-01-29 Oxyrane Uk Limited Methods and materials for reducing degradation of recombinant proteins
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease

Also Published As

Publication number Publication date
WO2011039634A9 (en) 2011-11-10
JP6392263B2 (ja) 2018-09-19
US20170226493A1 (en) 2017-08-10
CN104651428A (zh) 2015-05-27
CA2775938C (en) 2021-08-10
BR112012007099A2 (pt) 2015-09-15
KR101824743B1 (ko) 2018-02-05
JP2016104043A (ja) 2016-06-09
CA2775938A1 (en) 2011-04-07
KR20170116254A (ko) 2017-10-18
WO2011039634A2 (en) 2011-04-07
US10392609B2 (en) 2019-08-27
KR102000383B1 (ko) 2019-07-15
ES2783024T3 (es) 2020-09-16
JP2013505735A (ja) 2013-02-21
US9598682B2 (en) 2017-03-21
EP2483399A2 (en) 2012-08-08
US20130158239A1 (en) 2013-06-20
EP2483399B1 (en) 2019-03-27
DK2483399T3 (da) 2019-05-13
CN102712914A (zh) 2012-10-03
KR20120107936A (ko) 2012-10-04
WO2011039634A3 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
JP6392263B2 (ja) ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解
JP6151183B2 (ja) マンノース−１−ホスホ−６−マンノース結合からキャップを外すことおよびリン酸化ｎ−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法
JP6131190B2 (ja) リン酸化ｎ−グリカンの脱マンノシル化
HK1171248B (en) Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
HK1171248A (en) Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160812

R150 Certificate of patent or registration of utility model

Ref document number: 5990102

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees